A detailed history of Jpmorgan Chase & CO transactions in Nuvalent, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 34,709 shares of NUVL stock, worth $3.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,709
Previous 32,045 8.31%
Holding current value
$3.16 Million
Previous $2.43 Million 46.09%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$67.44 - $112.17 $179,660 - $298,820
2,664 Added 8.31%
34,709 $3.55 Million
Q2 2024

Aug 12, 2024

SELL
$62.76 - $81.61 $178,238 - $231,772
-2,840 Reduced 8.14%
32,045 $2.43 Million
Q1 2024

May 10, 2024

SELL
$72.35 - $88.99 $1.05 Million - $1.29 Million
-14,460 Reduced 29.3%
34,885 $2.62 Million
Q4 2023

Feb 12, 2024

BUY
$42.42 - $80.28 $359,806 - $680,934
8,482 Added 20.76%
49,345 $3.63 Million
Q3 2023

Nov 14, 2023

BUY
$39.12 - $49.85 $155,775 - $198,502
3,982 Added 10.8%
40,863 $1.88 Million
Q2 2023

Aug 11, 2023

SELL
$23.58 - $44.68 $8.97 Million - $17 Million
-380,323 Reduced 91.16%
36,881 $1.56 Million
Q1 2023

May 18, 2023

BUY
$25.42 - $33.52 $391,976 - $516,878
15,420 Added 3.84%
417,204 $10.9 Million
Q1 2023

May 11, 2023

SELL
$25.42 - $33.52 $626,399 - $825,999
-24,642 Reduced 5.78%
401,784 $10.5 Million
Q4 2022

Feb 13, 2023

BUY
$18.46 - $36.37 $6,184 - $12,183
335 Added 0.08%
426,426 $12.7 Million
Q3 2022

Nov 14, 2022

SELL
$13.55 - $19.92 $194,591 - $286,071
-14,361 Reduced 3.26%
426,091 $8.28 Million
Q2 2022

Aug 11, 2022

SELL
$7.4 - $15.07 $15,710 - $31,993
-2,123 Reduced 0.48%
440,452 $5.97 Million
Q1 2022

May 11, 2022

BUY
$11.65 - $19.57 $593,334 - $996,700
50,930 Added 13.0%
442,575 $6.15 Million
Q4 2021

Feb 10, 2022

BUY
$18.01 - $30.1 $6.98 Million - $11.7 Million
387,542 Added 9445.33%
391,645 $7.46 Million
Q3 2021

Nov 12, 2021

BUY
$18.25 - $38.35 $74,879 - $157,350
4,103 New
4,103 $93,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.92B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.